Physician profile
Jonathan Ross
NPI 1194712208
$18,937.89
in general payments reported to CMS, 2019-2025
56 companies · $2,819 in 2025
The $2,819 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,439 · 2020: $1,077 · 2021: $1,965 · 2022: $2,441 · 2023: $4,364 · 2024: $2,832 · 2025: $2,819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,147 · Travel and Lodging: $1,855 · Education: $13.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,147.04 |
| Travel and Lodging | $1,854.89 |
| Education | $13.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,270.68 | 2019-2025 | |
| Ucb, INC. | $3,123.48 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Sk Life Science, INC. | $1,026.79 | 2020-2025 | Xcopri |
| Sunovion Pharmaceuticals INC. | $753.78 | 2019-2022 | |
| Lilly USA, LLC | $724.48 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Neurelis, INC. | $569.63 | 2020-2025 | Valtoco |
| Amgen INC. | $548.27 | 2019-2025 | Uplizna |
| Abbvie INC. | $539.95 | 2021-2025 | Ubrelvy, Qulipta |
| Jazz Pharmaceuticals INC. | $489.48 | 2020-2025 | |
| Argenx US, INC. | $438.14 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $409.69 | 2019-2024 | Vumerity |
| Kyowa Kirin, INC. | $400.15 | 2021-2024 | Nourianz |
| Emd Serono, INC. | $346.90 | 2019-2022 | |
| Eisai INC. | $325.28 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $305.92 | 2023-2024 | Aptiom |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.